Nipah virus Infections and Infestations
Conditions
Interventions
The first six participants recruited to the trial will be enrolled to cohort 1. These six individuals will be non-randomly allocated to group 1A, an open-label lead-in group. These six participants wi
group 2B will receive a dose of 5 x 10e10 viral particles of ChAdOx1 NipahB intramuscularly on day 0 followed by saline placebo on day 84, and group 2C will receive a dose of inactivated polio vaccine
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged between 18 to 55 years (inclusive) at the time of screening. 2. Medically healthy, such that, according to investigator judgement, hospitalisation within the study period is not anticipated, and the participant appears likely to be able to remain a study participant through the end of protocol-specified follow-up. Planned elective procedures for pre-existing conditions are allowable. 3. Able to attend the scheduled visits and comply with all study procedures. 4. Willing and able to give informed consent for participation in the study. 5. Agreement to refrain from blood donation during the course of the study. 6. For women of childbearing potential only (as defined by protocol section 8.5): willing to use effective contraception from one month prior to receiving the first dose of vaccine and for the duration of the study AND have a negative pregnancy test on the days of screening and vaccination.
Exclusion criteria
Exclusion criteria: 1. Participation in another research study involving an investigational product or other study which includes procedures that could compromise the integrity of this study (such as significant volumes of blood already taken) within the 12 weeks prior to enrolment, or are planning to do so within the trial period. 2. Previous immunisation with an investigational Nipah vaccine. 3. Reported or documented history of previous confirmed or suspected Nipah infection. 4. Administration of immunoglobulins and/or any blood products within three months preceding the planned administration of the vaccine candidate. 5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; severe infection(s); receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months, or long-term systemic corticosteroid therapy (including for more than 7 consecutive days within three months preceding the planned administration of the vaccine candidate). 6. History of anaphylaxis in relation to vaccination. 7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including hypersensitivity to the active substance or to any of the excipients of the IMP (EDTA or magnesium chloride). 8. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). 10. History of any serious psychiatric condition likely to affect participation in the study. 11. For women only: participants who are pregnant, breastfeeding or lactating, or are planning pregnancy during the course of the study. 12. History of a bleeding disorder (e.g. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 13. History of confirmed major thrombotic event (including cerebral venous sinus thrombosis, deep vein thrombosis, pulmonary embolism); history of antiphospholipid syndrome, or history of heparin-induced thrombocytopenia. 14. History of capillary leak syndrome. 15. Moderate, severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, haematological, immunological, endocrine disorder, or neurological illness (note, mild well-controlled co-morbidities in a healthy participant are acceptable as judged by the Investigator) 16. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units per week. 17. Suspected or known injecting drug use within the 5 years preceding enrolment. 18. Detectable circulating hepatitis B surface antigen (HBsAg). 19. Seropositive for hepatitis C virus (antibodies to HCV). 20. Any clinically significant finding on screening that is either unlikely to resolve or does not resolve (for example, on repeat testing at the discretion of an Investigator) within the recruitment timeline of the study. 21. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer if included in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data. Temporary Exclusion Criteria: The following applies to both vaccination visits. If the temporary exclusion resolves within the time constraints of the trial visits, the participant can
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Safety Outcome Measures: 1. Occurrence of solicited local reactogenicity signs and symptoms at 7 days following each vaccination (D0 to D6; V2 to V2+6) 2. Occurrence of solicited systemic reactogenicity signs and symptoms at 7 days following each vaccination (D0 to D6; V2 to V2+6) 3. Occurrence of unsolicited adverse events (AEs) at 28 days following each vaccination (D0 to D28; V2 to V2+28) 4. Occurence of abnormal safety laboratory measures (D0, D7, D14, D28, V2, V2+7, V2+14, V2+28) 5. Occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs) for the whole duration of the study (D0 to V2+281) Primary Immunogenicity Outcome Measure: 1. NipahB glycoprotein G-specific serological response as measured by ELISA (D0, D28, V2, V2+28) | — |
Secondary
| Measure | Time frame |
|---|---|
| NipahB glycoprotein G-specific serological response as measured by ELISA (D0, D7, D14, D28, V2, V2+7, V2+14, V2+28, V2+281) | — |
Countries
Bangladesh
Contacts
Public ContactLilli Hahn
Outcome results
None listed